Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus - PubMed (original) (raw)
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
Christina Pfirschke et al. Int J Oncol. 2009 Apr.
Abstract
Oncolytic virotherapy, a new type of cancer therapy involving viruses with oncolytic and immunostimulatory potential, is based on tumor selective viral replication, resulting in a specific lysis of tumor cells. Effective tumor targeting of oncolytic viruses remains a major problem because only a fraction of systemically applied viruses can reach the tumor tissue. We describe for the first time in an in vitro co-culture system that T lymphocytes can be loaded with Newcastle disease virus (NDV) in such a way that the virus load will be transferred to the tumor target cells upon contact of the T cells with tumor cells. The effectiveness of this NDV 'hitchhiking' on T cells can be influenced by the amount of virus, the ratio of T cells to tumor cells, the activation status of the T cells and by the virulence of the virus as shown by flow cytometry, quantitative real-time PCR and fluorescence microscopy. In a tumor neutralization assay in vitro, monolayers of human tumor cells could be completely and effectively destroyed by the addition of polyclonally activated human T cells loaded with oncolytic NDV. This process involves the formation of large T cell clusters as revealed by phase-contrast microscopy. Loading of oncolytic NDV onto activated T cells and adoptive transfer into a tumor-bearing host might enhance the efficacy of adoptive T cell therapy of tumors as well as tumor targeting of oncolytic viruses.
Similar articles
- Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.
Shobana R, Samal SK, Elankumaran S. Shobana R, et al. J Virol. 2013 Apr;87(7):3792-800. doi: 10.1128/JVI.02394-12. Epub 2013 Jan 23. J Virol. 2013. PMID: 23345509 Free PMC article. - Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K, Song C, Kong L, Hu L, Lin G, Ye T, Yao G, Wang Y, Chen H, Cheng W, Barr MP, Liu Q, Zhang G, Ding C, Meng S. Jiang K, et al. BMC Cancer. 2018 Jul 18;18(1):746. doi: 10.1186/s12885-018-4522-3. BMC Cancer. 2018. PMID: 30021550 Free PMC article. - Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting.
Wu Q, Jin Y, Li S, Guo X, Sun W, Liu J, Li Q, Niu D, Zou Y, Du X, Li Y, Zhao T, Li Z, Li X, Ren G. Wu Q, et al. Int Immunopharmacol. 2024 Jul 30;136:112305. doi: 10.1016/j.intimp.2024.112305. Epub 2024 May 31. Int Immunopharmacol. 2024. PMID: 38823178 - Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V. Schirrmacher V. Expert Opin Biol Ther. 2015;15(12):1757-71. doi: 10.1517/14712598.2015.1088000. Epub 2015 Oct 5. Expert Opin Biol Ther. 2015. PMID: 26436571 Review. - Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Kalyanasundram J, Hamid A, Yusoff K, Chia SL. Kalyanasundram J, et al. Acta Trop. 2018 Jul;183:126-133. doi: 10.1016/j.actatropica.2018.04.007. Epub 2018 Apr 4. Acta Trop. 2018. PMID: 29626432 Review.
Cited by
- Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
Schirrmacher V, van Gool S, Stuecker W. Schirrmacher V, et al. Int J Mol Sci. 2022 Oct 27;23(21):13050. doi: 10.3390/ijms232113050. Int J Mol Sci. 2022. PMID: 36361831 Free PMC article. Review. - Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A, Calistri A, Altomonte J. Reale A, et al. Pharmaceutics. 2021 Dec 18;13(12):2192. doi: 10.3390/pharmaceutics13122192. Pharmaceutics. 2021. PMID: 34959474 Free PMC article. Review. - Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.
Schirrmacher V, van Gool S, Stuecker W. Schirrmacher V, et al. Biomedicines. 2019 Aug 30;7(3):66. doi: 10.3390/biomedicines7030066. Biomedicines. 2019. PMID: 31480379 Free PMC article. Review. - Oncolytic viruses: overcoming translational challenges.
Martinez-Quintanilla J, Seah I, Chua M, Shah K. Martinez-Quintanilla J, et al. J Clin Invest. 2019 Mar 4;129(4):1407-1418. doi: 10.1172/JCI122287. eCollection 2019 Mar 4. J Clin Invest. 2019. PMID: 30829653 Free PMC article. Review. - Cell carriers for oncolytic viruses: current challenges and future directions.
Roy DG, Bell JC. Roy DG, et al. Oncolytic Virother. 2013 Oct 9;2:47-56. doi: 10.2147/OV.S36623. eCollection 2013. Oncolytic Virother. 2013. PMID: 27512657 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources